Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT06411028

Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia

Led by Radboud University Medical Center · Updated on 2025-03-24

60

Participants Needed

3

Research Sites

125 weeks

Total Duration

On this page

Sponsors

R

Radboud University Medical Center

Lead Sponsor

C

Canisius-Wilhelmina Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Tremor occurs in up to 55% of dystonia patients, which is known as dystonic tremor syndrome (DTS). Tremor can be present in the body part affected by dystonia (dystonic tremor, DT), or an unaffected body part (tremor associated with dystonia, TAWD). DTS can be treated with botulinum neurotoxin (BoNT) injections, but BoNT is effective in only about 60-70% of patients. It is unknown which patients benefit most from BoNT treatment. The investigators aim to explore the associations between clinical and pathophysiological tremor characteristics and BoNT efficacy. To do so, the investigatorswill measure clinical, electrophysiological, ultrasonographic and (functional) magnetic resonance imaging ((f)MRI) characteristics before the start of BoNT treatment and measure BoNT efficacy after three three-monthly BoNT sessions.

CONDITIONS

Official Title

Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Clinical diagnosis of dystonic tremor or tremor associated with dystonia according to the 2018 consensus statement on the classification of tremors
  • Tremor of one or both upper extremities
  • Starting botulinum toxin injections as part of normal clinical practice
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • Acquired cause of dystonic tremor syndrome
  • More than 4 consecutive previous botulinum toxin treatments in the upper extremity to be treated
  • Last botulinum toxin injection within 6 months before study if treated 3 or fewer times consecutively
  • Unstable medication dose for dystonia or tremor within 1 month before study
  • Deep brain stimulation implanted within 6 months before study
  • Unstable deep brain stimulation settings within 1 month before study
  • Other health conditions interfering with study participation
  • Known allergy to Dysport components
  • Infection in the upper extremity
  • Pregnancy, trying to conceive, or breastfeeding
  • Insufficient knowledge of Dutch or English
  • Contraindications for MRI such as previous brain surgery, claustrophobia, active implants, epilepsy, or incompatible metal objects
  • Moderate to severe head tremor while lying down
  • Unable to provoke postural tremor while lying down

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Donders Centre for Cognitive Neuroimaging

Nijmegen, Gelderland, Netherlands, 6525 EN

Actively Recruiting

2

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands, 6525 GA

Actively Recruiting

3

Canisius-Wilhelmina Ziekenhuis

Nijmegen, Gelderland, Netherlands, 6532 SZ

Actively Recruiting

Loading map...

Research Team

I

Iris Visser, MSc

CONTACT

R

Rick Helmich, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia | DecenTrialz